Vivoryon Therapeutics N.V. Employee Directory
Biotechnology ResearchSaxony-Anhalt, Germany11-50 Employees
Vivoryon Therapeutics N.V. is a clinical-stage biotechnology company based in Halle, Saxony-Anhalt, Germany, focused on developing innovative small-molecule medicines for inflammatory and fibrotic kidney disorders. The company aims to alter disease progression by modulating the activity and stability of pathologically relevant proteins, with the goal of improving patient outcomes. Its lead program, varoglutamstat, is a proprietary, first-in-class, orally available inhibitor of QPCT/L being evaluated for diabetic kidney disease. As a small-scale biotech, it concentrates on scientific development within the biotechnology research sector. A notable regulatory development occurred in 2024 when the U.S. FDA granted Fast Track designation for varoglutamstat in early Alzheimer's disease. The company maintains ongoing engagement with investors and the broader scientific community through events and governance activities, such as annual meetings.
1-888-653-2347 
support@leadiq.com 
